Form 4: Paragon 28 Director Kristina Wright Reports Disposal of Shares Following Merger with Zimmer Biomet
SEC Form 4 Filing
Kristina Wright, a director at Paragon 28, reported the disposal of common stock due to the merger with Zimmer Biomet, where each share was converted into cash and a contingent value right.
Summary
- Kristina Wright, a director of Paragon 28, filed a Form 4 indicating changes in beneficial ownership.
- The filing is related to the merger between Paragon 28 and Zimmer Biomet Holdings, Inc.
- As a result of the merger, each share of Paragon 28 common stock was converted into $13.00 in cash and one contingent value right (CVR).
- Wright disposed of 32,118 shares of common stock as a result of the merger on April 21, 2025.
- Outstanding restricted stock units subject to time-based vesting also vested and were canceled, with holders receiving cash and CVRs for each share.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The merger provides a cash payout and a potential future payment via CVR, but the CVR's value is contingent.
Risks
- The contingent value right (CVR) payment is dependent on the achievement of specified milestones, which introduces uncertainty regarding the potential payout.
Future Outlook
The future payout of the Contingent Value Right (CVR) is dependent on the achievement of specific milestones outlined in the CVR Agreement.
Industry Context
The acquisition of Paragon 28 by Zimmer Biomet reflects a trend of consolidation in the medical device industry, where larger companies acquire smaller, specialized firms to expand their product portfolios and market reach.
Comparison to Industry Standards
- Mergers and acquisitions are common in the medical device industry, with companies like Medtronic and Stryker also actively acquiring smaller players to enhance their offerings.
- Contingent Value Rights (CVRs) are sometimes used in acquisitions to bridge valuation gaps and align the interests of both parties, as seen in other deals within the pharmaceutical and biotech sectors.
Stakeholder Impact
- Shareholders received $13.00 in cash per share and a Contingent Value Right (CVR).
- Employees of Paragon 28 are now part of Zimmer Biomet.
Key Dates
| Date | Description |
|---|---|
| January 28, 2025 | Date of the Agreement and Plan of Merger between Paragon 28, Zimmer Biomet Holdings, Inc., and Gazelle Merger Sub I, Inc. |
| April 21, 2025 | Date of the earliest transaction and the effective time of the merger, resulting in the disposal of shares. |
Keywords
Merger, Zimmer Biomet, Paragon 28, Contingent Value Right, Form 4, Beneficial Ownership, Wright, Director
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.